Oily Skin: Drugs That Cause It and Medications That Treat It

Why Skin Becomes Oily: The Sebaceous Gland and Androgen Axis

Oily skin results from overactive sebaceous glands, which are concentrated on the face, scalp, and upper trunk. Sebum is a lipid mixture of triglycerides, wax esters, squalene, and free fatty acids that protects skin barrier function and prevents transepidermal water loss.

Androgen-Driven Sebum Production

The primary driver of sebum output is androgen signaling. Dihydrotestosterone (DHT), converted from testosterone by 5-alpha reductase within the sebaceous gland itself, binds intracellular androgen receptors and upregulates lipogenesis [1]. A 2009 study in the Journal of Investigative Dermatology demonstrated that sebocyte proliferation increases linearly with DHT concentration across a 10-fold dosing range in vitro [2]. This explains why puberty, polycystic ovary syndrome (PCOS), and exogenous androgen therapy all provoke oiliness.

Other Hormonal Influences

Insulin-like growth factor 1 (IGF-1), growth hormone, and certain neuropeptides (substance P, corticotropin-releasing hormone) also stimulate sebocytes [3]. High-glycemic diets raise IGF-1 and insulin, which may partly explain the dietary link some patients report. A randomized controlled trial (N=43) published in the American Journal of Clinical Nutrition found that a low-glycemic-load diet reduced non-inflammatory acne lesion counts by 23.5% over 12 weeks compared to a control diet [4].

Genetic and Environmental Factors

Twin studies estimate that 81% of the variance in sebum excretion rate is heritable [5]. Humidity and heat increase sebum flow rate. Age progressively lowers output: sebum production peaks in the late teens and declines approximately 23% per decade after age 20 in both sexes [1].

Medications That Cause or Worsen Oily Skin

A range of prescription drugs upregulate sebum either through direct androgenic effects or through secondary hormonal pathways. When patients present with new-onset oiliness, a thorough medication reconciliation should be the first step.

Testosterone and Anabolic Steroids

Exogenous testosterone is the most common pharmacologic cause of oily skin. In the Testosterone Trials (TTrials, N=790), skin oiliness was reported by 15 to 25% of men randomized to transdermal testosterone gel versus 3 to 5% on placebo [6]. Supraphysiologic doses used in bodybuilding produce near-universal seborrhea. The Endocrine Society's 2018 clinical practice guideline lists acne and oily skin among expected androgenic side effects and recommends monitoring at 3 to 6 months after TRT initiation [7].

Progestins With Androgenic Activity

Levonorgestrel, norethindrone, and norgestrel have partial androgen-receptor agonist activity. Women using levonorgestrel-only oral contraceptives or levonorgestrel intrauterine systems (Mirena) sometimes develop oiliness and acne within the first 3 to 6 months [8]. Switching to a less androgenic progestin (desogestrel, drospirenone, or norgestimate) often resolves the issue.

Corticosteroids, Lithium, and Other Culprits

Systemic corticosteroids promote sebaceous gland hypertrophy through IGF-1 and insulin pathway activation, particularly at doses above prednisone 20 mg daily for more than 2 weeks. Lithium carbonate stimulates sebocyte differentiation directly; seborrheic dermatitis occurs in up to 35% of lithium-treated patients [9]. Other reported offenders include phenytoin, isoniazid, and cyclosporine. DHEA supplements, available over the counter, are metabolized to androstenedione and testosterone, producing a dose-dependent rise in sebum [10].

Growth Hormone and Growth-Hormone Secretagogues

Recombinant human growth hormone and peptides such as ipamorelin, CJC-1295, and MK-677 (ibutamoren) raise IGF-1 levels. Because IGF-1 synergizes with androgens at the sebocyte, patients on growth hormone secretagogue therapy frequently report oily skin and new acne within 4 to 8 weeks. No large randomized trial has isolated the sebum endpoint, but a retrospective cohort of 87 adults on GH replacement found a 42% incidence of self-reported increased oiliness at 6 months [11].

First-Line Treatments: Isotretinoin and Oral Retinoids

When oily skin is severe enough to warrant systemic treatment (almost always accompanied by acne), isotretinoin is the most effective agent available.

How Isotretinoin Suppresses Sebum

Isotretinoin (13-cis-retinoic acid) induces sebaceous gland apoptosis and reduces gland volume by up to 90% over a standard 16 to 24 week course at 0.5 to 1.0 mg/kg/day [12]. Sebum excretion rate drops within 2 to 4 weeks and remains suppressed for months to years after discontinuation. A 2014 meta-analysis in the Journal of the American Academy of Dermatology (JAAD) pooling 24 studies (N=3,836) confirmed sustained remission in 67.6% of patients after a single course of isotretinoin [13].

Dosing, Monitoring, and iPLEDGE

Standard dosing is 0.5 mg/kg/day for month one, escalated to 1.0 mg/kg/day as tolerated, targeting a cumulative dose of 120 to 150 mg/kg. The FDA's iPLEDGE program mandates monthly pregnancy tests, two forms of contraception in females of reproductive potential, and liver function plus lipid panel monitoring at baseline and monthly during therapy.

"Isotretinoin remains the only medication that can induce long-term remission of severe acne and seborrhea by fundamentally altering sebaceous gland biology," according to the American Academy of Dermatology's 2024 acne management guidelines [14].

Low-Dose Isotretinoin Protocols

For patients whose primary complaint is oiliness rather than cystic acne, some dermatologists prescribe low-dose isotretinoin (10 to 20 mg daily or 20 mg three times weekly). A prospective study (N=60) published in the Journal of Dermatological Treatment demonstrated a 72% reduction in casual sebum level at 12 weeks on 20 mg every other day, with significantly fewer mucocutaneous side effects than full-dose therapy [15].

Anti-Androgen Therapy: Spironolactone and Beyond

For women who cannot take or prefer to avoid isotretinoin, anti-androgen medications offer an alternative pathway to sebum control.

Spironolactone

Spironolactone, a potassium-sparing diuretic, competitively blocks the androgen receptor and inhibits 5-alpha reductase. Off-label use at 50 to 200 mg daily reduces sebum production and acne in women. A retrospective study of 395 women published in the Journal of the American Academy of Dermatology showed 85% improvement in acne with spironolactone monotherapy at a mean dose of 100 mg/day, with 66% rated as "clear" or "almost clear" by month 12 [16].

Safety and Monitoring

Spironolactone carries a risk of hyperkalemia. The Endocrine Society recommends checking serum potassium at baseline, 1 month, and then every 6 to 12 months in otherwise healthy women under 45. Menstrual irregularity occurs in 10 to 20% of patients. Spironolactone is pregnancy category X due to anti-androgenic effects on male fetal development.

"For adult female acne driven by hormonal factors, spironolactone 100 mg daily is a reasonable first-line systemic option before isotretinoin," notes the British Association of Dermatologists' 2024 acne guideline [17].

Other Anti-Androgens

Cyproterone acetate (available in Europe and Canada, not the US) is a potent progestational anti-androgen used at 2 mg in combination with ethinyl estradiol (marketed as Diane-35). Flutamide has been studied but carries hepatotoxicity risks that limit clinical use [18]. Finasteride and dutasteride, 5-alpha reductase inhibitors, reduce DHT but are rarely prescribed solely for oily skin. A small crossover trial (N=28) in the British Journal of Dermatology found dutasteride 0.5 mg daily reduced facial sebum by 28% at 24 weeks [19].

Combined Oral Contraceptives for Sebum Control

Four combined oral contraceptives (COCs) carry FDA approval for acne treatment, and all four reduce sebum production through suppression of ovarian androgens and elevation of sex hormone-binding globulin (SHBG).

FDA-Approved COCs for Acne

The approved formulations are ethinyl estradiol/norgestimate (Ortho Tri-Cyclen), ethinyl estradiol/norethindrone acetate/ferrous fumarate (Estrostep Fe), ethinyl estradiol/drospirenone (Yaz), and ethinyl estradiol/drospirenone/levomefolate (Beyaz). In ACOG's Practice Bulletin No. 110, COCs are recommended as first-line therapy for women with acne who also desire contraception [20].

Efficacy Data

A Cochrane systematic review (31 trials, N=12,579) found that COCs reduced both inflammatory and non-inflammatory acne lesion counts compared to placebo, with drospirenone-containing pills showing superiority over levonorgestrel-containing pills for inflammatory lesions [21]. Sebum reduction typically becomes measurable by cycle 3 and plateaus at cycle 6.

Choosing the Right Progestin

When selecting a COC specifically for sebum control, the progestin component matters most. The hierarchy from most to least anti-androgenic: drospirenone > dienogest > desogestrel > norgestimate > norethindrone > levonorgestrel. Patients switching from a levonorgestrel-containing COC to a drospirenone-containing COC should expect 8 to 12 weeks before clinical improvement.

Topical Treatments That Reduce Oiliness

Topical therapies target the skin surface and upper pilosebaceous unit, making them suitable for mild to moderate seborrhea or as adjuncts to systemic therapy.

Topical Retinoids

Tretinoin (0.025 to 0.1%), adapalene (0.1 to 0.3%), and tazarotene (0.045 to 0.1%) normalize follicular keratinization and exert modest direct effects on sebocyte differentiation. Adapalene 0.3% gel reduced sebum excretion by 18% at 12 weeks in a vehicle-controlled study (N=150) [22]. The FDA approved adapalene 0.1% for over-the-counter sale (Differin) in 2016, broadening access for patients with oily skin and mild acne.

Niacinamide

Topical niacinamide (nicotinamide) 2 to 5% reduces casual sebum excretion rate by 17 to 24% over 4 weeks according to a double-blind split-face study (N=50) published in the Journal of Cosmetic and Laser Therapy [23]. The mechanism involves inhibition of sebocyte lipogenesis. Because it is available without prescription and has minimal side effects, niacinamide is a practical first step for patients whose oiliness does not warrant prescription therapy.

Topical Antiandrogens and Emerging Agents

Clascoterone cream 1% (Winlevi) received FDA approval in August 2020 as the first topical androgen receptor inhibitor for acne. In two phase 3 trials (N=1,440 combined), clascoterone applied twice daily reduced total lesion counts significantly versus vehicle at 12 weeks [24]. While its labeled indication is acne vulgaris (not isolated oily skin), its anti-androgen mechanism directly addresses sebum overproduction without systemic exposure. Sebum-specific data from post-hoc analyses are anticipated.

When to Seek Medical Evaluation for Oily Skin

Most oily skin is a cosmetic concern, not a medical emergency. But certain patterns warrant evaluation.

Red Flags

Sudden-onset oiliness in a postmenopausal woman or a prepubertal child may signal an androgen-secreting tumor of the adrenal or ovary. Associated virilization signs (hirsutism, clitoromegaly, voice deepening) should prompt urgent measurement of serum total testosterone, DHEA-sulfate, and 17-hydroxyprogesterone [25]. A total testosterone level above 200 ng/dL in a woman or rapidly progressive virilization warrants imaging (CT abdomen, pelvic ultrasound) within 2 weeks.

PCOS Screening

In reproductive-age women presenting with oily skin plus irregular menses, acne, or hirsutism, polycystic ovary syndrome (PCOS) should be considered. The Rotterdam criteria require two of three: oligo-anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. The AACE/ACE 2023 guidelines recommend screening for metabolic syndrome and type 2 diabetes in all PCOS patients at diagnosis [26].

Drug-Induced Oiliness: What to Tell Your Clinician

If oily skin developed within 1 to 3 months of starting a new medication, bring the medication list and a timeline to your appointment. In many cases, dose adjustment (lowering testosterone dose to target mid-normal trough levels, for example) or switching to an alternative formulation resolves the issue without stopping therapy entirely.

Building a Treatment Ladder for Oily Skin

Not every patient with oily skin needs isotretinoin. A stepped approach matches treatment intensity to symptom severity and patient goals.

Step 1: Non-Prescription Measures

Oil-free cleansers twice daily, topical niacinamide 4%, blotting films, and non-comedogenic moisturizers form the baseline. A low-glycemic diet may offer modest benefit over 8 to 12 weeks [4].

Step 2: Topical Prescriptions

Topical retinoids (adapalene 0.1 to 0.3% or tretinoin 0.025%), clascoterone cream 1%, or benzoyl peroxide (when acne coexists) add targeted sebum suppression.

Step 3: Systemic Hormonal Therapy (Women)

Spironolactone 50 to 100 mg daily, a drospirenone-containing COC, or the combination of both. Response takes 2 to 3 months.

Step 4: Isotretinoin

Reserved for refractory cases, severe oiliness with nodulocystic acne, or patients who have failed steps 1 through 3. Low-dose protocols (10 to 20 mg daily) can address oiliness with fewer side effects.

For men on TRT, the treatment ladder differs: topical retinoids and benzoyl peroxide are mainstays. Spironolactone and COCs are not options. Dose reduction of testosterone or switching from short-acting (cypionate) to longer-acting (undecanoate) formulations may smooth hormonal peaks that drive sebum surges.

Patients starting isotretinoin for persistent drug-induced oiliness should have serum lipids and liver transaminases checked at baseline, 1 month, and every 2 months thereafter per AAD guidelines [14].